GSK Commits £400 Million to Establish Major Cambridge R&D Center, Consolidating UK Research Operations
GlaxoSmithKline plc (GSK) (NYSE: GSK) announced plans to establish a major new global R&D center...
GSK
GSK’s Dovato Demonstrates Non-Inferior Efficacy to Biktarvy in Phase IIIb VOGUE HIV Study
GlaxoSmithKline plc (GSK) (NYSE: GSK) announced results from the Phase IIIb VOGUE study conducted by...
GSK Submits Bexsero Label Update to EMA for Single-Dose Booster in Adolescents and Adults Previously Vaccinated in Childhood
GlaxoSmithKline plc (GSK) (NYSE: GSK) announced that the European Medicines Agency (EMA) has accepted a...
GSK Reports Mixed Phase III Results for Camlipixant in Refractory Chronic Cough: CALM-1 Trial Meets Primary Endpoint While CALM-2 Falls Short
GlaxoSmithKline plc (GSK) (NYSE: GSK) announced mixed results from the CALM-1 and CALM-2 Phase III...
GSK Terminates $2.2 Billion Neurodegenerative Disease Partnership with Alector Following Dual Clinical Failures
GlaxoSmithKline plc (GSK) (NYSE: GSK) has formally terminated its neurodegenerative disease research collaboration with Alector,...
Sino Biopharmaceutical Expands GSK Partnership to Commercialize Trelegy and Anoro Ellipta in China
Sino Biopharmaceutical Limited (HKG: 1177) announced an expanded strategic partnership with GlaxoSmithKline plc (GSK, NYSE:...
GSK and Spero Therapeutics Secure FDA Approval for Utebzi, First Oral Carbapenem Antibiotic for Complicated UTIs
GlaxoSmithKline plc (GSK) (NYSE: GSK) and Spero Therapeutics (NASDAQ: SPRO) announced that the U.S. Food...
GSK’s Momelotinib Receives Orphan Drug Designation from FDA and EMA for VEXAS Syndrome, Addressing Critical Unmet Need in Rare Myeloid Disorder
GlaxoSmithKline plc (GSK) (NYSE: GSK) announced that momelotinib has received Orphan Drug Designation (ODD) from...
GSK to Acquire Nuvalent for $10.6 Billion, Adding Breakthrough Lung Cancer Therapies to Oncology Portfolio
GlaxoSmithKline plc (GSK) (NYSE: GSK) announced today a definitive agreement to acquire Nuvalent, Inc. (NASDAQ:...
Sino Biopharmaceutical and GSK Report 19% Functional Cure Rate with Bepirovirsen in Phase III Hepatitis B Studies at EASL 2026
Sino Biopharmaceutical Limited (HKG: 1177) announced positive results from two Phase III clinical studies, B-Well...
GSK Restructures China Vaccine Business with Dedicated Shingrix and Engerix-B Teams
GlaxoSmithKline plc (GSK) (NYSE: GSK) has restructured its vaccine business operations in China, splitting the...
GSK’s Arexvy RSV Vaccine Receives Expanded Japanese Approval for Adults 18-49 at Increased Risk
GlaxoSmithKline plc (GSK) (NYSE: GSK) announced that Japan’s Ministry of Health, Labour and Welfare (MHLW)...
GSK Partners with Sino Biopharmaceutical’s CTTQ Subsidiary to Commercialize Bepirovirsen in China’s Hepatitis B Market
GlaxoSmithKline plc (GSK, NYSE: GSK) has announced a strategic licensing agreement with Jiangsu Chia Tai...
GSK Reports Solid Q1 2026 Results – Specialty Medicines and Shingrix Drive Growth as Company Maintains Strong 2031 Outlook
GlaxoSmithKline plc (GSK, NYSE: GSK) released its first-quarter 2026 financial results on May 6, 2026,...
SiranBio Inks $1.005B Licensing Deal with GSK for First-in-Class siRNA Therapy SA030 Targeting ALK7 in Cardiometabolic Disease
SiranBio, a Suzhou-based siRNA drug developer, announced a strategic licensing agreement with GlaxoSmithKline plc (GSK;...
GSK’s Efimosfermin Receives Dual Regulatory Designations for MASH Treatment – Breakthrough Therapy and PRIME Status Support Phase III Development
GlaxoSmithKline plc (GSK, NYSE: GSK) announced on April 27, 2026, that efimosfermin, a once-monthly investigational...
GSK Acquires 35Pharma for $950 Million to Secure Best-in-Class Pulmonary Arterial Hypertension Therapy HS235
GlaxoSmithKline plc (GSK, NYSE: GSK) has completed its acquisition of 35Pharma Inc., a Canadian biopharmaceutical...
China’s NHSA Selects 31 Innovative Drugs for Historic Reference Drug Pre-Communication Program
The National Healthcare Security Administration (NHSA) has published the inaugural list of 31 innovative drugs...
GSK’s B7-H4 ADC Mocertatug Rezetecan Shows 62-67% Response Rates in Phase I Ovarian and Endometrial Cancer Trials
GlaxoSmithKline plc (GSK, NYSE: GSK) has reported highly promising data from the global Phase I...
GSK’s Exdensur Secures Second NMPA Approval in China for Chronic Rhinosinusitis with Nasal Polyps, Expanding Type 2 Inflammation Portfolio
GlaxoSmithKline plc (GSK, NYSE: GSK) announced that China’s National Medical Products Administration (NMPA) has granted...